A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study) Diego Casas Deza; Ana Belén Julián Gomara; Eva Caudevilla Biota; Belén Beltrán; Eugeni Domènech; Ana Gutiérrez Casbas; Miriam Mañosa; Yamile Zabana; Lourdes Roc Alfaro; Emilio Valverde Romero; Elena García González; Beatriz Sicilia; Viviana Laredo; Maria José Alcalá Escriche; Lucia Madero Velázquez; Rocío Ferreiro-Iglesias; Antonia Palmero Pérez; Margalida Calafat; Saioa Rubio Iturria; Irene Moraleja Yudego; Yolanda Ber Nieto; Sandra García Mateo; Javier P. Gisbert; Raquel Vicente Lidón; Lara Arias; Erika Alfambra; Ana Belén Doñate Borao; Elena Peña González; Pilar Corsino Roche; Miren Vicuña Arregui; Ainara Elorza; Manuel Domínguez Cajal; María Chaparro; Manuel Barreiro-de Acosta; Santiago García-López;

Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn¿s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED) Eugeni Domènech; Andreea Ciudin; José María Balibrea; Eduard Espinet-Coll; Fiorella Cañete; Lilliam Flores; Manuel Ferrer-Márquez; Román Turró; Alejandro Hernández-Camba; Yamile Zabana; Ana Gutiérrez;

Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study Rodrigo Bremer Nones; Eron Fabio Miranda; Gustavo de Nardi Marçal; Fernanda da Silva Barbosa Baraúna; Marcela Rocha Loures; Paula Cenira Senger; Daniela Oliveira Magro; Paulo Gustavo Kotze;